At the current share price, PKI has a trailing P/E of about 6. The market for biotech tools and instruments may be weak, but I don’t think it’s as weak as implied by today’s price action. Moreover, a big chunk of PKI’s revenue comes from annuity-like service contracts.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.